Quantcast
Last updated on April 16, 2014 at 17:34 EDT

Latest Nephrotic syndrome Stories

2010-11-10 18:21:54

The Halpin Foundation and the American Society of Nephrology (ASN) proudly highlight the research advances in membranous nephropathy made possible by The Halpin Foundation-ASN Research Grant, created to help young faculty develop independent research careers. This award provides recipients transition funding toward successful application for an NIH RO1 grant. Elena Torban, PhD (McGill University Faculty of Medicine), the 2008 recipient of The Halpin Foundation-ASN Research Grant, recently...

2010-11-03 05:01:00

UNION CITY, Calif., Nov. 3, 2010 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (Nasdaq: QCOR) today announced that the commercial launch is now underway for H.P. Acthar® Gel (repository corticotropin injection) as monotherapy for the treatment of Infantile Spasms (IS) in infants and children under the age of two years. This new Acthar indication was approved by the U.S. Food and Drug Administration (FDA) on October 15, 2010. Acthar provides an important treatment...

2010-10-28 15:05:00

ANAHEIM, Calif., Oct. 28 /PRNewswire-FirstCall/ -- Questcor Pharmaceuticals, Inc. (Nasdaq: QCOR) today reported financial results for the quarter ended September 30, 2010. Net sales totaled $31.3 million and net income was $11.5 million or $0.18 per diluted common share for the quarter ended September 30, 2010. The Company's financial performance was driven primarily by an increase in net sales for Acthar in the treatment of acute exacerbations of multiple sclerosis (MS). Acthar net sales...

2010-10-25 05:30:00

ANAHEIM, Calif., Oct. 25 /PRNewswire-FirstCall/ -- Questcor Pharmaceuticals, Inc. (Nasdaq: QCOR) announced today that it will present at the 21st Annual Oppenheimer Healthcare Conference at 1:00 p.m. ET on Wednesday, November 3, 2010 at The Waldorf-Astoria Hotel in New York. Don M. Bailey, President and Chief Executive Officer, will review the Company's business strategy and recent corporate developments. Attendance at this conference is by invitation only. A live audio and slides...

2010-10-15 08:29:00

ANAHEIM, Calif., Oct. 15 /PRNewswire-FirstCall/ -- Questcor Pharmaceuticals, Inc. (Nasdaq: QCOR) today announced the U.S. Food and Drug Administration (FDA) has approved Questcor's supplemental new drug application (sNDA) for H.P. Acthar® Gel (repository corticotropin injection) in the treatment of infantile spasms (IS), an ultra-rare orphan disorder affecting approximately 2,000 American children annually. IS is a devastating and potentially life-threatening form of...

2010-09-20 05:30:00

UNION CITY, Calif., Sept. 20 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (Nasdaq: QCOR) announced today that it will present at the UBS Global Life Sciences Conference on Wednesday, September 22, 2010 at The Grand Hyatt Hotel in New York. Don M. Bailey, President and Chief Executive Officer, will discuss the Company's business strategy and historical financial performance at 3:30 p.m. Eastern Time. Attendance at this conference is by invitation only. A live audio and slides webcast of...

2010-07-29 05:30:00

UNION CITY, Calif., July 29 /PRNewswire-FirstCall/ -- Questcor Pharmaceuticals, Inc. (Nasdaq: QCOR) announced today that it will participate in the following upcoming investor conferences: The BMO Capital Markets 10th Annual Focus on Healthcare Conference Thursday, August 5, 2010 New York, NY 4:00 p.m. ET Webcast available at: http://www.bmocm.com/conferences/ 2010healthcare/webcast Collins Stewart 2010 Health Care Event Wednesday, August 11, 2010...

2010-07-28 15:05:00

UNION CITY, Calif., July 28 /PRNewswire-FirstCall/ -- Questcor Pharmaceuticals, Inc. (Nasdaq: QCOR) today reported financial results for the second quarter ended June 30, 2010. The Company's financial performance was driven primarily by a 145% year-over-year increase in the number of new paid Acthar prescriptions for the treatment of multiple sclerosis (MS) exacerbations as compared to the second quarter of 2009. Net sales totaled a record $28.3 million for the quarter ended June...

2010-07-16 13:23:28

First morning albumin:creatinine urine test clues clinicians into signs of trouble A morning urine test is superior to all other tests for detecting declining kidney performance in patients with diabetic kidney disease, according to a study appearing in an upcoming issue of the Journal of the American Society Nephrology (JASN). The results suggest that clinicians should monitor kidney function by measuring the albumin:creatinine ratio from a first morning urine sample. Individuals with kidney...

2a76e0f1b2ad409ea92af682628763211
2010-06-11 06:45:00

Bevacizumab Increases the Risk of Severe Urinary Protein Loss by More than 4- Fold The widely used cancer drug bevacizumab (known popularly as Avastin) may cause severe loss of protein from the kidney into the urine that can lead to significant kidney damage and can compromise the efficacy of cancer treatment, according to a study appearing in an upcoming issue of the Journal of the American Society of Nephrology (JASN). The results suggest that physicians should monitor patients' kidney...